他汀类药物对肝外胆管癌风险的影响
该病例对照研究纳入394例肝外胆管癌(ECC)合并高脂血症患者与788例年龄、性别、种族、族裔和居住地匹配的高脂血症对照,评估他汀使用与ECC风险及生存的关系。结果显示他汀使用与ECC风险显著降低相关(OR 0.22),且与远端胆管癌(dCCA)患者总生存改善相关(HR 0.53)。
要点
- 他汀使用与肝外胆管癌风险显著降低相关(OR 0.22)。
- 他汀使用与远端胆管癌患者总生存改善相关(HR 0.53)。
- 中等强度他汀剂量与ECC风险降低相关(OR 0.48)。
核心结论
- 他汀使用可能降低肝外胆管癌风险,并可能改善远端胆管癌患者生存。
研究设计与样本
- 病例对照研究,纳入2005至2015年Mayo Clinic Rochester的394例ECC合并高脂血症患者,按年龄、性别、种族、族裔和居住地匹配788例高脂血症对照。
主要发现
- 他汀使用者中病例组73例(19%),对照组403例(51%)。
- 他汀使用与所有ECC风险显著降低相关(OR 0.22;95%CI 0.16-0.29)。
- 他汀使用与pCCA风险降低相关(OR 0.3;95%CI 0.21-0.41)。
- 他汀使用与dCCA风险降低相关(OR 0.06;95%CI 0.03-0.14)。
- 中等强度剂量他汀与ECC风险降低相关(OR 0.48;95%CI 0.34-0.67;P<0.001)。
临床怎么用
- 对于合并高脂血症的患者,他汀使用可能与肝外胆管癌风险降低相关,尤其远端胆管癌。
- 他汀使用可能改善远端胆管癌患者生存,但需进一步验证研究。
局限性
- 研究为病例对照设计,需额外验证研究确认结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Statins have been proven to be cytotoxic to human cholangiocarcinoma cells by inhibiting cell division and inducing apoptosis. We aimed to determine the effect of statin use on the risk of cancer development and survival in patients with extrahepatic cholangiocarcinoma (ECC), including perihilar cholangiocarcinoma (pCCA) and distal cholangiocarcinoma (dCCA). APPROACH AND RESULTS: A total of 394 patients with ECC and hyperlipidemia who received care at Mayo Clinic Rochester between 2005 and 2015 were matched by age, sex, race, ethnicity, and residency to 788 controls with hyperlipidemia. Clinical and outcome data were abstracted. The odds ratios (ORs) for risk and hazard ratios for outcomes were calculated. The mean age and standard deviation (SD) for cases and controls was 65.6 years (13.8). The number of statin users in cases and controls was 73 (19%) and 403 (51%), respectively. Hepatitis C virus infection (OR, 15.84; 95% confidence interval [CI], 4.06-61.87; P < 0.001) was the most significant risk factor for pCCA followed by inflammatory bowel disease and cirrhosis, whereas other liver disease, including biliary stone disease (OR, 4.06; CI, 2.24-7.36; P < 0.001), was the only significant risk factor for dCCA. Statin use was associated with significantly reduced risk for all ECC (OR, 0.22; CI, 0.16-0.29) as well as for the subtypes pCCA (OR, 0.3; CI, 0.21-0.41) and dCCA (OR, 0.06; CI, 0.03-0.14), all P < 0.0001. Moderate-intensity dosage was found to decrease the risk of ECC (OR, 0.48; CI, 0.34-0.67; P < 0.001). Comparing statin ever users to nonusers, patients with dCCA who used statins had significantly overall better survival (hazard ratio = 0.53; CI, 0.29-0.97; P = 0.04). CONCLUSIONS: This case-control study suggests that statins decrease the risk of ECC and may improve survival in patients with dCCA. Additional validation studies are warranted.
引用
- Lavu S, Therneau TM, Harmsen WS, et al. Effect of Statins on the Risk of Extrahepatic Cholangiocarcinoma. Hepatology. 2020. PMID: 32119126. doi:10.1002/hep.31146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。